EFFADOL-K: Effectiveness of a Patient Therapeutic Education Program in Improving Pain Management

Sponsor
Centre Francois Baclesse (Other)
Overall Status
Recruiting
CT.gov ID
NCT03297723
Collaborator
National Cancer Institute, France (Other)
220
16
71.4
13.8
0.2

Study Details

Study Description

Brief Summary

Pain is one of the most feared and burdensome symptoms experienced by cancer patients. Its prevalence has been estimated by INCa1 in 2012 at 48% in patients undergoing cancer treatment, and unrelieved pain is directly associated with significantly reduced quality of life (QoL)2. A large part of cancer pain undertreatment can be attributed to patient-related barriers. Patient barriers are multifactorial and often result from a lack of knowledge about cancer pain and its self-management. They mainly consist of misconceptions about opioids and their side effects, nonadherence, and reluctance to alert health care providers to unrelieved pain. Patient education enables people with chronic disease to manage their illness, and has been considered in the field of cancer research as an important strategy to achieve optimal pain control.

In Basse-Normandie french region, the "Health Regional Plan, pain aspect" has identified the theme " pain education program " as a priority.

The main endpoint is the decrease of pain interference with daily life (using the Brief Pain Inventory). The experimental group, consisting of cancer pain patients, will benefit from the education program by previously trained health care providers. It will be compared with the control group, consisting with patients whose pain will be conventionally managed before the professional training in therapeutic education.

Condition or Disease Intervention/Treatment Phase
  • Other: Therapeutic education Programm

Study Design

Study Type:
Observational
Anticipated Enrollment :
220 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Effectiveness of a Patient Therapeutic Education Program in Improving Pain Management
Actual Study Start Date :
Dec 18, 2017
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental arm

The experimental group will be constituted after the medical staff was trained to TPE. Cancer patients will benefit from a PEP aiming at learning how to better manage their pain.

Other: Therapeutic education Programm
Intervention will include: an identification of educational needs and expectations, a bilateral agreement between patient and medical staff on the priority skills acquirement, a structured educational activities tailored to the patient's need. the making of an educational record.

Controle arm

The control group will be constituted before the training of the medical staff to TPE. Patients' pain will be managed conventionally.

Outcome Measures

Primary Outcome Measures

  1. the decrease of pain impact on daily life activities based on a decrease of 2 points (on a 0-10 scale) between mean values measured before and after the PEP (at 1 month). [1 month]

Secondary Outcome Measures

  1. The proportion of patients adhering to the full ETP program (3 workshops), [1 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient suffering from a cancer which diagnosis has been established since at least 1 month

  • Patient who suffers from pain related to the pathology or its treatment:

  • receiving an analgesic treatment since at least 1 month

  • moderate to severe pain intensity in the previous week : average pain score greater than 4 (on a 0-10 numerical rating scale), OR pain leading to insomnia OR 4 daily breakthrough pain, which interferes with daily activities

  • Patient with a life expectancy > or = 6 months

  • Health compatible with the PEP requirements (WHO performance scale > or = 2)

  • Patient v 18 years old

  • Patient able to understand, speak and read French

  • Patient without cognitive dysfunctions

  • Patient with a signed informed consent before inclusion in the study

Exclusion Criteria:
  • Primary central nervous system or cerebral metastases

  • Disorders of higher functions documented

  • Evolutionary psychiatric pathology

  • Drug user

  • Abuse of alcohol exceeding WHO recommendations

  • Refusal of participation

Contacts and Locations

Locations

Site City State Country Postal Code
1 centre Hospitalier d'Alençon Alençon France
2 Centre Hospitalier d'Argentan Argentan France
3 Centre Hospitalier AVRANCHES-GRANVILLE Avranches France
4 Centre Hospitalier Bayeux Bayeux France
5 Centre François Baclesse Caen France
6 CHU CAEN Caen France
7 Hopital privé Paul d'Egine Champigny-sur-Marne France
8 Centre Hospitalier de Cherbourg Cherbourg-Octeville France
9 Ch Dieppe Dieppe France
10 Centre Hospitalier de Flers Flers France
11 Centre Oscar Lambret Lille France
12 Centre Hospitalier Lisieux Lisieux France
13 Hopital Européen Georges Pompidou (HEGP) Paris France
14 Centre Hospitalier de Saint-lo Saint-Lô France
15 Ghpso Senlis Senlis France
16 IGR Villejuif France

Sponsors and Collaborators

  • Centre Francois Baclesse
  • National Cancer Institute, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Francois Baclesse
ClinicalTrials.gov Identifier:
NCT03297723
Other Study ID Numbers:
  • 2016-A01405-46
First Posted:
Sep 29, 2017
Last Update Posted:
May 18, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of May 18, 2021